Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Ask the ExpertFull Access

Discussing Mild Cognitive Impairment

Published Online:18 Aug 2021https://doi.org/10.1176/appi.focus.20210008

Abstract

Dr. Purganan reports that her spouse has served on an advisory board for Dova Pharmaceuticals and Targeted Oncology, has served as a speaker for the Chronic Liver Disease Foundation/Focus Medical Communications, has received research funding from Arrowhead Pharmaceuticals, and has received sponsored travel for research support from Arrowhead Pharmaceuticals and Genfit/Covance.